Clinical Proteomics Clinical Biochemistry
Plasma extracellular vesicles from osteosarcoma patients display distinct cytokine signatures
Abstract
Background Osteosarcoma (OS), a rare and aggressive cancer of the bone, is typically diagnosed on the basis of extensive imaging and tissue biopsy. Currently, there are no biomarkers that can be used for diagnosis, early detection, or monitoring of OS. Plasma extracellular vesicles (EVs) provide a minimally invasive source of potential biomarkers that can be analyzed through liquid biopsy. Methods EVs from plasma samples of Finnish OS patients ( n = 15) and healthy controls ( n = 24) were isolated by ultracentrifugation and characterized by nanoparticle tracking analysis, electron microscopy and Western blotting. EVs were analyzed using a proximity extension assay (PEA) for the quantification of 89 cytokines and immune-related proteins. Differential protein expression was determined by Student’s t test corrected for multiple testing. The association of protein expression with tumor grade was determined by analysis of variance. Diagnostic assessment of selected protein levels in plasma and EVs was performed with receiver operating characteristic (ROC) curves. Results After adjusting for multiple testing, 13 proteins were significantly deregulated in patients’ plasma EVs compared with healthy controls. Among these proteins, CCL25 was the most upregulated protein in patient plasma EVs (adjusted odds ratio = 3.2, P = 0.011). The expression of several downregulated proteins was associated with tumor grade. Further analysis of plasma proteins by ELISA also revealed significantly higher CCL25 levels in OS patients than in controls. However, according to the area under the ROC curve, CCL25, CCL13, and CXCL13 demonstrated superior diagnostic performance when assessed with PEA in plasma EVs compared to measurements obtained from plasma using ELISA. Conclusion We demonstrated that plasma EVs from OS patients exhibit a distinct cytokine profile by PEA and identified CCL25 as a potential diagnostic biomarker of OS. Validation in independent, larger cohorts is needed to confirm the diagnostic utility of CCL25.